Publications by authors named "Paul Meisner"

Claim this Profile
I
Incidence and prevalence of antiphospholipid syndrome (APS) in the USA (2016-2019): a retrospective database study.
Meheni Khellaf, Paul Meisner, Maria Sarno, Piotr Zaremba, Adam Jedrzejczyk

BMJ Open· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis.
E Michael Lewiecki, Tomasz Blicharski, Stefan Goemaere, Kurt Lippuner, Paul D Meisner

J Clin Endocrinol Metab· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study.
Michael R McClung, Jacques P Brown, Adolfo Diez-Perez, Heinrich Resch, John Caminis, Paul Meisner

J Bone Miner Res· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Romosozumab FRAME Study: A Post Hoc Analysis of the Role of Regional Background Fracture Risk on Nonvertebral Fracture Outcome.
Felicia Cosman, Daria B Crittenden, Serge Ferrari, E Michael Lewiecki, Juan Jaller-Raad, Paul D Meisner

J Bone Miner Res· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
Kenneth G Saag, Jeffrey Petersen, Maria Luisa Brandi, Andrew C Karaplis, Mattias Lorentzon, Paul D Meisner

N Engl J Med· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Romosozumab Treatment in Postmenopausal Women with Osteoporosis.
Felicia Cosman, Daria B Crittenden, Jonathan D Adachi, Neil Binkley, Edward Czerwinski, Paul D Meisner

N Engl J Med· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized double-blind, placebo-controlled efficacy and safety study of ALO-02 (extended-release oxycodone surrounding sequestered naltrexone) for moderate-to-severe chronic low back pain treatment.
Richard L Rauck, Martin E Hale, Almasa Bass, Candace Bramson, Glenn Pixton, Paul Meisner

Pain· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter, 12-month, open-label, single-arm safety study of oxycodone-hydrochloride/naltrexone-hydrochloride extended-release capsules (ALO-02) in patients with moderate-to-severe chronic noncancer pain.
Samir Arora, Beatrice Setnik, Drass Michael, John D Hudson, Ray Clemmer, Paul Meisner

J Opioid Manag· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Looking from the outside in: the use of video in attachment-based interventions.
Miriam Steele, Howard Steele, Jordan Bate, Hannah Knafo, Michael Kinsey, Paul Meisner

Attach Hum Dev· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of placebo response in pooled lamotrigine neuropathic pain clinical trials.
Michael C Irizarry, David J Webb, Zahid Ali, Boris A Chizh, Michael Gold, Paul D Meisner

Clin J Pain· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis